Novo Nordisk, one of the world’s leading pharmaceutical powerhouses, is entering a pivotal transition period. The company has announced that longtime executive Maziar “Mike” Doustdar will become the new President and CEO, stepping in officially on August 7. His appointment follows the abrupt departure of Lars Fruergaard Jørgensen earlier this year and comes at a time when the company is re-evaluating its near-term growth trajectory.
Simultaneously, Novo Nordisk has adjusted its full-year financial outlook downward — a move that sent shockwaves through the market and triggered a sharp decline in its stock price. At one point, shares dropped by over 25%, before slightly recovering to close the day 23% lower.
The revision is largely attributed to slower-than-expected performance in the U.S. for two of the company’s flagship products: Wegovy, its market-leading weight loss treatment, and Ozempic, its highly popular diabetes medication.
Strategic Headwinds: U.S. Market Complexity and Competitive Pressure
Despite being at the forefront of the GLP-1 drug revolution, Novo Nordisk is now confronting a more complex landscape in its most important market. The company cited multiple challenges affecting sales performance — including the ongoing presence of compounded GLP-1 alternatives, a tempered expansion of the obesity treatment market, and intensifying competition from rival manufacturers.
These dynamics have forced the Danish drugmaker to temper expectations for both sales and operating profits in 2025. Full-year revenue growth is now forecasted at 8% to 14%, significantly reduced from the previous range of 13% to 21%. Similarly, profit growth projections have been trimmed to 10% to 16%.
Novo Nordisk had already lowered its outlook earlier this year following underwhelming first-quarter results, and its upcoming second-quarter earnings announcement, scheduled for August 6, is expected to be scrutinized closely by investors and analysts alike.
New CEO, New Chapter
The appointment of Mike Doustdar represents more than a leadership change — it signals a potential shift in operational tone. A veteran of Novo Nordisk since 1992, Doustdar brings global experience from Europe, Asia, and Latin America, and has most recently served as Executive Vice President of International Operations.
In a formal statement, Chairman Helge Lund framed the appointment as a strategic decision to “guide Novo Nordisk through its next chapter of growth.” Doustdar echoed that ambition, noting that he steps into the role with a “sense of urgency” and a commitment to elevate performance while broadening patient access to innovative treatments.
Investor Confidence Under Pressure
Despite its stature as a leader in obesity and diabetes care, Novo Nordisk’s recent market performance underscores the risks of relying heavily on a narrow portfolio of high-growth blockbusters. The company’s stock has declined more than 40% since the beginning of the year, with investor sentiment further weakened by underwhelming trial results for its next-generation obesity drug candidate, CagriSema.
However, the company remains optimistic that headwinds may subside in the latter half of the year. Supply-related challenges in the U.S. market are expected to ease, and the phase-out of unauthorized compounded alternatives could restore momentum for Wegovy and Ozempic.
Partner With Us
Want to feature your brand, business, or service on 365247 — Whether you’re looking to sponsor, collaborate, or build presence within our ecosystem, we’d love to explore it with you.
Submit Your Interest Here
